🧬 BioMed Pulse · 2026-07-12 02:01 UTC

BIOMED PULSE

July 12, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Ebola Bundibugyo virus outbreak in DRC and Uganda has now surpassed 1,460 confirmed cases and 452 deaths as of July 1, making it the dominant global health emergency of 2026. The overall mood is cautious and urgent: a landmark treatment trial just opened enrollment in DRC, but geographic spread continues and the PHEIC declared in May remains active. ^{[1] [2] [3]}

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS - DRC AND UGANDA

• As of July 1, 2026, the Bundibugyo virus disease (BVD) outbreak has logged 1,460 confirmed cases and 452 deaths in DRC, with ongoing cross-border transmission into Uganda reported across multiple WHO Disease Outbreak News updates. ^[1]
• WHO declared the outbreak a Public Health Emergency of International Concern (PHEIC) on May 17, 2026, noting it does not yet meet the threshold for a pandemic emergency per the IHR Emergency Committee. ^{[3] [4]}
• Africa CDC and WHO jointly launched a continental preparedness and response plan on June 5, 2026, seeking to raise US$518 million to support African countries. ^[5]
• The PARTNERS clinical trial opened patient enrollment in DRC on July 2, 2026, aiming to identify the first effective treatments specifically for Bundibugyo virus disease. ^[2]
• WHO added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing on July 2, 2026, enabling rapid genetic-material-based confirmation from blood samples. ^[6]
• WHO issued its first comprehensive clinical management guidelines for all filovirus diseases, covering all Ebola and Marburg virus types, on June 17, 2026, timed to support the active outbreak response. ^[7]
• CDC issued a statement on July 10, 2026, reaffirming its mobilization to the DRC-Uganda Ebola response, with enhanced airport screening already operating at Washington-Dulles and Atlanta Hartsfield-Jackson. ^{[8] [9]}

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

• WHO's fifth Disease Outbreak News report (July 2, 2026) confirmed the Andes hantavirus (ANDV) outbreak remains linked to passengers aboard the cruise ship M/V Hondius, first reported May 2, 2026, with additional confirmed cases since the previous update. ^[10]
• CDC's June 24, 2026, hantavirus response transcript confirms ongoing U.S. government monitoring; early reports identified 7 initial cases (2 confirmed, 5 suspected) among 147 passengers and crew.

NIPAH VIRUS - INDIA (KERALA)

• On June 11, 2026, Kerala State confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district - an adult male who developed neurological symptoms on May 30 and was hospitalized June 10.
• Earlier in 2026, two NiV cases were confirmed in West Bengal (Barasat, North 24 Parganas) in January among healthcare workers at the same private hospital, and one confirmed case was reported in Rajshahi Division, Bangladesh in February.

MPOX - RECOMBINANT STRAIN

• WHO reported in February 2026 that a recombinant monkeypox virus (MPXV) strain combining genetic elements of both clade Ib and clade IIb has been documented in two cases, a known but previously rare natural process.

AVIAN INFLUENZA A(H9N2) - ITALY

• Italy notified WHO on March 21, 2026, of one human case of avian influenza A(H9N2) in an adult male who had returned from Senegal; next-generation sequencing confirmed the subtype.

YELLOW FEVER - GLOBAL

• WHO's June 24, 2026, Disease Outbreak News reported 79 human yellow fever infections across six countries from January 1 to May 26, 2026, following increased transmission in the Americas throughout 2025 that carried into this year.

MEASLES - BANGLADESH

• Bangladesh notified WHO on April 4, 2026, of a nationwide measles surge affecting 58 of 64 districts across all eight divisions; 19,161 suspected cases and 2,897 laboratory-confirmed cases reported.

WEST NILE VIRUS - UNITED STATES

• CDC warned on July 1, 2026, that the 2026 West Nile season is tracking at record early-season case counts and urged Americans to use mosquito bite prevention during the Independence Day holiday weekend.

E. COLI - FROZEN BLUEBERRIES, UNITED STATES

• CDC posted a food safety alert on July 7, 2026, linking a multistate E. coli outbreak to frozen blueberries and advising consumers not to eat the recalled product.

🧬 LONGEVITY & AGING

NAD-PLUS HOMEOSTASIS AND BONE REPAIR IN AGING

• A new Europe PMC study describes a senescent metabolism-modulating hierarchical scaffold that restores NAD-plus homeostasis and redox balance in aged tissue, tested specifically in a bone repair model - pointing toward biomaterial-based approaches that target metabolic aging hallmarks rather than just structural deficits.

KAEMPFEROL FROM MORINGA AND LONGEVITY IN DROSOPHILA

• Researchers publishing in Toxicology Reports found that kaempferol extracted from Moringa oleifera increases lifespan and reduces efavirenz-induced functional senescence markers in Drosophila melanogaster, suggesting the flavonoid may counteract drug-accelerated aging biology at the cellular level.

DELIRIUM AS A LINK BETWEEN SEVERE INFECTION AND DEMENTIA

• Two commentary pieces in Lancet Healthy Longevity (Sipila and Kivimaki; Penfold et al.) argue that delirium following severe infection may be a mechanistic bridge to subsequent dementia, a potentially actionable insight since delirium is both common in hospitalized older adults and currently under-treated.

TAU, EMERIN, AND NEURONAL NUCLEAR MECHANICS IN AGING

• A study in Nucleus journal found that the mechanically sensitive nuclear envelope protein emerin is elevated by tau accumulation in neurons, linking nuclear mechanotransduction to tau-driven cytoskeletal remodeling - a pathway relevant to Alzheimer's and other tauopathies of aging.

HYPERTENSION AND FRAILTY IN OLDER INDIAN ADULTS

• A letter in Blood Pressure (July 2026) responding to the Longitudinal Ageing Study in India adds evidence that hypertension independently associates with frailty among middle-aged and older adults, reinforcing cardiovascular control as a lever for extending healthspan in low- and middle-income countries.

MULTIPLE LONG-TERM CONDITIONS AND KIDNEY DISEASE MORTALITY

• The NURTuRE-CKD multicentre cohort study, published in Annals of Medicine, found that accumulation of multiple long-term conditions significantly accelerates mortality, progression to kidney failure, and deterioration in health-related quality of life among people with chronic kidney disease.

METABOLIC LIVER DISEASE BURDEN TIED TO TOBACCO, 1990-2038

• A study in Journal of Diabetes and Metabolic Disorders projected the global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) attributable to tobacco from 1990 to 2023 with projections to 2038, underscoring tobacco as an underappreciated driver of liver aging and metabolic disease.

NITRATE SUPPLEMENTATION TO BOOST EXERCISE BENEFITS IN OLDER ADULTS (TRIAL)

• ClinicalTrials.gov lists a study (NCT07572266) examining adjuvant dietary nitrate as a strategy to amplify exercise-induced health benefits in older adults, targeting aging hallmarks including physical, mental, and metabolic impairments that compromise healthspan.

💊 NEW CURES & APPROVALS

TRUTAKNA (ATACIEPT-VYMJ) - VERA THERAPEUTICS INC.

• openFDA records show an original approval (ORIG AP) for TRUTAKNA, a biologic active ingredient listed as ataciept-VYMJ, sponsored by Vera Therapeutics Inc. under BLA761486; ataciept is a fusion protein that blocks two B-cell survival factors (BAFF and APRIL) used in autoimmune indications including IgA nephropathy.

VARENICLINE TARTRATE - SOMERSET THERAPS LLC

• openFDA records show an original approval (ORIG AP) for a varenicline tartrate formulation by Somerset Theraps LLC (ANDA219382); varenicline is a nicotinic receptor partial agonist indicated for smoking cessation.

RINVOQ LQ (UPADACITINIB) - ABBVIE

• openFDA records reflect a supplemental approval (SUPPL AP) for RINVOQ LQ, Abbott's JAK1 inhibitor upadacitinib in liquid formulation (NDA218347), which is used across multiple inflammatory and autoimmune indications.

INBRIJA (LEVODOPA INHALATION POWDER) - MERZ

• openFDA records show a supplemental approval (SUPPL AP) for INBRIJA by Merz (NDA209184); this inhaled levodopa formulation is used for off episodes in Parkinson's disease patients on carbidopa/levodopa regimens.

RYALTRIS (MOMETASONE FUROATE PLUS OLOPATADINE HYDROCHLORIDE) - GLENMARK SPECIALTY

• openFDA records show a supplemental approval (SUPPL AP) for RYALTRIS nasal spray by Glenmark Specialty (NDA211746), a fixed-dose combination corticosteroid plus antihistamine indicated for allergic rhinitis.

🧪 CLINICAL TRIALS

PARTNERS TRIAL - BUNDIBUGYO VIRUS DISEASE TREATMENTS, DRC

• WHO announced on July 2, 2026, that the PARTNERS clinical trial has opened enrollment for patients in DRC, representing the first major international effort to evaluate potential therapeutics specifically for Bundibugyo virus disease in a live outbreak setting. ^[2]

ADJUVANT NITRATE TO BOOST EXERCISE-INDUCED BENEFITS IN OLDER ADULTS

• NCT07572266 on ClinicalTrials.gov is evaluating whether dietary nitrate supplementation can enhance the multimodal anti-aging benefits of exercise in older adults, with aging hallmarks including metabolic, physical, and cognitive impairments listed as primary targets.

IL-12 GENETICALLY ENGINEERED MYELOID CELLS IN SOLID TUMORS

• NCT07672483 is a pilot study testing IL-12-producing genetically engineered myeloid cells (IL-12 GEMys) in participants with relapsed or refractory solid tumors, aiming to harness innate immune cells already present in tumors to deliver localized cytokine-mediated tumor killing.

BRINCIDOFOVIR IV FOR PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

• NCT07511049 is a pilot study evaluating intravenous brincidofovir as an antiviral treatment for progressive multifocal leukoencephalopathy (PML), a rare fatal JC virus brain infection occurring in immunocompromised patients with no currently approved therapies.

177LU-DOTA-EB-TATE FOR ONCOCYTIC THYROID CANCER

• NCT06991738 is testing the radioligand 177Lu-DOTA-EB-TATE, which targets a protein overexpressed on Hurthle cell (oncocytic) thyroid cancer cells, in adults with metastatic radioactive-iodine non-responsive disease - a rare cancer with very few existing treatment options.

CATCHU MULTISENSORY FALLS ASSESSMENT

• NCT05544760, updated July 10, 2026, is evaluating quantitative multisensory integration measures as clinical tools for falls risk assessment, linking visual-somatosensory processing deficits to fall outcomes in aging populations.

📢 PUBLIC HEALTH

CANCER CASES PROJECTED TO NEARLY DOUBLE BY 2050

• A WHO report released July 8, 2026, projects new global cancer cases will nearly double to approach 40 million annually by 2050, against a current baseline of 20.6 million new cases and close to 10 million deaths per year, calling for urgent prevention and early detection investment.

WEST NILE EARLY SEASON ALERT - UNITED STATES

• CDC reported on July 1, 2026, that weekly emergency room visits for mosquito bites and West Nile-related illness are running higher than seasonal averages and encouraged use of EPA-registered insect repellents and elimination of standing water around homes.

INFANT BOTULISM AND NARA ORGANICS FORMULA

• CDC issued an outbreak update on June 13, 2026, urging parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula linked to an ongoing infant botulism outbreak.

LISTERIA OUTBREAK - REQUESÓN/SOFT RICOTTA CHEESE

• CDC warned on June 5, 2026, of a Listeria monocytogenes outbreak linked to requesón and soft ricotta cheese, advising consumers to avoid the implicated products.

WHO CANCER WARNING ENDORSED BY GLOBAL DATA

• WHO's July 8 cancer report documents more than 26,000 cancer deaths per day globally, with physical, emotional, and financial tolls cited as drivers for urgent scale-up of prevention, treatment, and palliative care infrastructure worldwide.

This edition of BIOMED PULSE is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for personal health decisions.

📎 Sources

1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
2. Patient enrolment begins in a scientific trial to identify the… — WHO News
3. Epidemic of Ebola Disease caused by Bundibugyo virus in the De… — WHO News
4. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
5. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
6. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
7. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
8. CDC Statement on Ebola Outbreak in the Democratic Republic of … — CDC Newsroom
9. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
10. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260712-02-v25 · 2026-07-12 02:01 UTC · pulse.uzylab.com